Intellia's One-Time CRISPR HAE Therapy Shows Four-Year Durability Ahead of March PDUFA
NTLA sits 35% above its 52-week low of $7.95 on light trading volume (0.2× avg).
Summary
Intellia rolled out seven ACAAI presentations for lonvo-z, its one-time in vivo CRISPR therapy for hereditary angioedema, and the durability numbers are the headline: mean plasma kallikrein reduction of 84% at four weeks held through up to four years, with at least 90% of Phase 1/2 patients attack-free in each month and 100% free of long-term prophylaxis at data cutoff. In the Phase 3 HAELO subgroup of 35 patients who entered on long-term prophylaxis, the mean attack rate fell 81% versus their prior prophylaxis and 63% achieved complete control, more than tripling their prior attack-free rate. Quality of life improved 23.5 points on AE-QoL at week 28 versus 6.5 for placebo, well past the 6-point clinically meaningful threshold, and the integrated 93-patient analysis showed an 89% attack rate reduction with 97% never starting prophylaxis after treatment. No new long-term safety risks were identified; TEAEs were mild to moderate with no serious events in the lonvo-z arm. This lands two months after the FDA accepted the BLA with Priority Review and a March 10, 2027 PDUFA date, and Intellia is hosting an investor webcast this morning to walk through the data and commercial launch prep. The March 10, 2027 PDUFA decision is the binary event that matters.
At the time of this announcement, NTLA was trading at $10.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $7.95 to $18.48. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.